Thursday, May 2, 2019

Novartis's Sandoz division has struck a deal with Taiwan's EirGenix Inc to market a biosimilar version of Roche's Herceptin that is now in late-stage development to treat some cancer tumors.


from Reuters: Health News https://reut.rs/2IUZsur

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner